IDEXX Laboratories Aktie
| 628,66USD | 1,60USD | 0,26% | 
WKN: 888210 / ISIN: US45168D1046
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 9 300 | 10 350 | 10 780 | 11 000 | 11 000 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 0,29 | 0,31 | 0,31 | 0,33 | 0,35 | 
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1 013 | 900 | 1 044 | 1 441 | 1 338 | 
| Summe Anlagevermögen | 1 281 | 1 537 | 1 703 | 1 819 | 1 955 | 
| Summe Aktiva | 2 295 | 2 437 | 2 747 | 3 260 | 3 293 | 
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1 662 | 1 747 | 2 138 | 1 775 | 1 698 | 
| Summe Eigenkapital | 633 | 690 | 609 | 1 485 | 1 595 | 
| Summe Passiva | 2 295 | 2 437 | 2 747 | 3 260 | 3 293 | 
Adresse
| One IDEXX Drive, 04092-2040 Westbrook | |
| Telefon | +1 (207) 556-0300 | 
| Internet | http://www.idexx.com | 
Management
| Andrew Emerson Chief Financial Officer, Treasurer & EVP | 
| Bruce L. Claflin Independent Director | 
| Daniel M. Junius Independent Director | 
| George J. Fennell Executive Vice President-Global CAG Commercial | 
| Irene Chang Britt Independent Director | 
| Jeffery Donn Chadbourne SVP-Commercial Finance & Sales Operations | 
| John Ravis Investor Relations Contact | 
| Jonathan J. Mazelsky President, Chief Executive Officer & Director | 
| Joseph L. Hooley Independent Director | 
| Julie Godon Senior Vice President & Global Marketing Officer | 
| Karen Peacock Independent Director | 
| Lawrence D. Kingsley Independent Non-Executive Chairman | 
| M. Anne Szostak Independent Director | 
| Martin Alexander Smith Executive VP-Global Operations, R&D | 
| Michael Erickson EVP & GM-Point of Care Diagnostics & Telemedicine | 
| Michael J. Lane Executive VP, GM-Diagnostic Solutions & IT | 
| Michael P. Johnson Chief Human Resources Officer & Executive VP | 
| Michael Schreck EVP, GM-Corporate Accounts & Customer Experience | 
| Murthy Yerramilli SVP-Assay, Instrument Research & Development | 
| Sam A. Samad Independent Director | 
| Sharon E. Underberg Secretary, Executive VP & General Counsel | 
| Sophie V. Vandebroek Independent Director | 
| Stuart M. Essig Independent Director | 
| Tina Hunt Executive VP-Global Strategy & Commercial | 
 
									 
									 
								